登录 注册 会员服务 联系我们

Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US

  • Published:2020-06-12 Issue:10 Volume:38 Page:1115-1121
  • ISSN:1170-7690
  • Container-title:PharmacoEconomics
  • language:en
  • Short-container-title:PharmacoEconomics

Author:

Padula William V.ORCID,Parasrampuria Sonal,Socal Mariana P.,Conti Rena M.,Anderson Gerard F.

Funder

Laura and John Arnold Foundation

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Reference18 articles.

1. Orphan Drug Act. Public Law 97-414. 97th Congress January; 1983. p. 2049–66.

2. U.S. Food and Drug Administration. General Provisions of the Orphan Drug Act. U.S. Code of Federal Regulations: 21 CFR 316. 1992.

3. U.S. Tax Cuts and Jobs Act. Public Law 115-97. In: December tC, editor. 2017.

4. Reaves ND. A model of effective health policy: the 1983 Orphan Drug Act. J Health Soc Policy. 2003;17(4):61–71.

5. Caton ML. Maryland’s Prescription Drug Affordability Board Bill set to take effect. The National Law Review. 2019.
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3